Pseudohypoparathyroidism. Disappearance of the resistance to parathyroid extract during treatment with vitamin D.
Serum immunoreactive parathyroid hormone (iPTH) levels were increased in a 15 year old girl with pseudohypoparathyroidism, hypocalcemia, hyperphosphatemia, and minimal phosphaturic and absent hypercalcemic responses to exogenous parathyroid extract (PTE). Following normalization of the serum calcium concentration with vitamin D, serum iPTH and phosphate concentrations returned to the normal range, and phosphaturia could be clearly stimulated and hypercalcemia induced by PTE. On the other hand, the urinary cyclic adenosine 3',5'-monophosphate (cyclic AMP) excretion could not be stimulated, suggesting that in this case, there appears to be no relationship between the urinary excretion of cyclic AMP and the phosphaturic effect of PTE. The minimal phosphaturic effect and the lack of hypercalcemic effects of PTE in untreated pseudohypoparathyroidism can be explained by the secondary hyperparathyroidism causing elevated iPTH levels rather than by a defect at the level of the receptor sites. A requirement of pharmacologic amounts of vitamin D per se, however, for the responsiveness of patients with pseudohypoparathyroidism to PTE cannot be ruled out.
D000293:Adolescent; D000328:Adult; D002118:Calcium / Q000097:blood / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D010710:Phosphates / Q000097:blood; D011547:Pseudohypoparathyroidism / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D013997:Time Factors; D014807:Vitamin D / Q000627:therapeutic use*
D010281:Parathyroid Hormone; D010710:Phosphates; D014807:Vitamin D; D003404:Creatinine; D002118:Calcium